INMUNE BIO INC. Interest Expense
INMUNE BIO INC. (INMB) reported Interest Expense of $0 for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-08.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2025-05-08
- INMUNE BIO INC. interest expense for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- INMUNE BIO INC. interest expense for the quarter ending 2024-12-31 was -$395.00K, a 184.58% decline year-over-year.
- INMUNE BIO INC. interest expense for the quarter ending 2024-09-30 was $145.00K, a 74.47% decline year-over-year.
- INMUNE BIO INC. interest expense for the quarter ending 2024-06-30 was $250.00K, a 60.38% decline year-over-year.
- INMUNE BIO INC. interest expense for fiscal 2023 was $2.28M, a 13.11% increase from fiscal 2022.
- INMUNE BIO INC. interest expense for fiscal 2022 was $2.01M.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month | Interest Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | -$395.00K derived: sum of 2 quarters · filed 2025-05-08 | -$250.00K derived: sum of 3 quarters · filed 2025-05-08 | $0.00 derived: sum of 4 quarters · filed 2025-05-08 | |
| 2024-12-31 | -$395.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2025-05-08 | -$250.00K derived: sum of 2 quarters · filed 2025-05-08 | $0.00 derived: sum of 3 quarters · filed 2025-05-08 | $357.00K 10-Q · filed 2025-05-08 | $789.00K 10-K · filed 2025-03-27 |
| 2024-09-30 | $145.00K 10-Q · filed 2024-10-31 | $395.00K derived: sum of 2 quarters · filed 2024-10-31 | $752.00K 10-Q · filed 2024-10-31 | $1.22M derived: sum of 4 quarters · filed 2025-03-27 | |
| 2024-06-30 | $250.00K 10-Q · filed 2024-08-01 | $607.00K 10-Q · filed 2024-08-01 | $1.07M derived: sum of 3 quarters · filed 2025-03-27 | $1.64M derived: sum of 4 quarters · filed 2025-03-27 | |
| 2024-03-31 | $357.00K 10-Q · filed 2024-05-09 | $824.00K derived: sum of 2 quarters · filed 2025-03-27 | $1.39M derived: sum of 3 quarters · filed 2025-03-27 | $2.02M derived: sum of 4 quarters · filed 2025-03-27 | |
| 2023-12-31 | $467.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $1.03M derived: sum of 2 quarters · filed 2025-03-27 | $1.67M derived: sum of 3 quarters · filed 2025-03-27 | $2.28M 10-K · filed 2025-03-27 | |
| 2023-09-30 | $568.00K 10-Q · filed 2024-10-31 | $1.20M derived: sum of 2 quarters · filed 2024-10-31 | $1.81M 10-Q · filed 2024-10-31 | ||
| 2023-06-30 | $631.00K 10-Q · filed 2024-08-01 | $1.24M 10-Q · filed 2024-08-01 | |||
| 2023-03-31 | $612.00K 10-Q · filed 2024-05-09 | ||||
| 2022-12-31 | $2.01M 10-K · filed 2024-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |